Loading...
uniQure Community
NasdaqGS:QURE Community- 1 Narratives written by author
- 0 Comments on narratives written by author
- 17 Fair Values set on narratives written by author
Community Investing Ideas
AMT-130 Approval Will Transform Huntington's Treatment Pipeline
Key Takeaways Accelerated approval of AMT-130 for Huntington's could significantly boost future revenues as it would be a pioneering treatment. Strategic financial actions and strong cash reserves provide resilience and flexibility, supporting pipeline advancement and likely improving margins.
1users have liked this narrative
0users have commented on this narrative
5users have followed this narrative
AN
US$34.94
56.0% overvalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue growth
190.37% p.a.
Profit Margin
5.81%
Future PE
141.06x
Share price in 2028
US$42.82